Northern Trust Corp lifted its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 0.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 645,195 shares of the medical instruments supplier’s stock after acquiring an additional 3,523 shares during the period. Northern Trust Corp owned 0.87% of West Pharmaceutical Services worth $60,984,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Acrospire Investment Management LLC purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter worth $113,000. Citigroup Inc. raised its holdings in shares of West Pharmaceutical Services by 95.1% during the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after acquiring an additional 765 shares during the period. Harfst & Associates Inc. purchased a new position in shares of West Pharmaceutical Services during the 1st quarter worth $186,000. Cambridge Investment Research Advisors Inc. raised its holdings in shares of West Pharmaceutical Services by 1.6% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 2,569 shares of the medical instruments supplier’s stock worth $210,000 after acquiring an additional 40 shares during the period. Finally, Bradley Foster & Sargent Inc. CT purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter worth $212,000. Institutional investors and hedge funds own 90.57% of the company’s stock.

Shares of West Pharmaceutical Services, Inc. (WST) opened at 94.99 on Thursday. West Pharmaceutical Services, Inc. has a one year low of $70.17 and a one year high of $99.91. The company has a 50-day moving average of $90.63 and a 200 day moving average of $90.59. The stock has a market capitalization of $7.03 billion, a price-to-earnings ratio of 40.77 and a beta of 1.12.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The firm had revenue of $397.60 million for the quarter, compared to the consensus estimate of $406.00 million. During the same period in the prior year, the business posted $0.59 earnings per share. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post $2.68 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Wednesday, October 18th will be given a dividend of $0.14 per share. The ex-dividend date is Tuesday, October 17th. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 annualized dividend and a yield of 0.59%. West Pharmaceutical Services’s dividend payout ratio is 22.22%.

WST has been the topic of several research analyst reports. Stephens initiated coverage on shares of West Pharmaceutical Services in a report on Tuesday. They issued an “equal weight” rating and a $99.00 price objective on the stock. BidaskClub lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Zacks Investment Research lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. Finally, Jefferies Group LLC upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and boosted their price objective for the company from $96.00 to $115.00 in a report on Friday, September 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $107.00.

WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/northern-trust-corp-has-60-98-million-stake-in-west-pharmaceutical-services-inc-wst/1609674.html.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.